An intranasal formulation of the corticosteroid ciclesonide has dose-dependent efficacy in patients with seasonal allergic rhinitis, according to a study presented at the 60th Annual Meeting of the American Association of Allergy, Asthma and Immunology (AAAAI) [San Francisco, US; March 2004]. Daily doses of intranasal ciclesonide 100 µg/day or 200 µg/day produced significant improvements in nasal symptoms, and had a tolerability profile similar to that of placebo, with the 200 µg/day dosage providing the greatest benefit.